Penny stocks attract attention when inflation, interest rate shifts and uneven global growth keep bigger markets choppy. The risk is that many small companies simply run out of cash before their plans play out. That is where the Elite Penny Stocks screener comes in, focusing on stocks with balance sheets that look better prepared for the long haul. For readers who want exposure to higher potential upside without ignoring basic financial strength, this article highlights 3 of the best picks from the screener that stand out in the current mix of inflation trends, central bank moves and shifting energy and trade conditions.

SIGA Technologies (SIGA)

Overview: SIGA Technologies is a commercial-stage pharmaceutical company focused on health security, with its lead product TPOXX used to treat human smallpox in the United States. The company operates in a niche segment tied to government and public health preparedness.

Operations: SIGA generates about US$93.8 million in revenue from its Pharmaceuticals segment, almost entirely from the United States.

Market Cap: US$258.9 million

For investors looking at resilient health-related exposure in the penny stock space, SIGA Technologies is a specialist in smallpox treatment with TPOXX and has a share price that currently trades below some estimates of fair value. Forecasts point to very strong earnings and revenue growth, even though margins have compressed and the company reported a recent quarterly loss, which underlines execution and funding risk. Governance quality appears solid, with a largely independent and experienced board, and the stock was recently added to Russell value and defensive indices, which can influence how institutions view the company. The mix of potential upside, recent underperformance and a higher risk balance sheet makes SIGA a stock many investors might want to look at more closely.

Resilient health security revenue, compressed margins and index inclusion make SIGA Technologies look like a story the market has not fully priced in yet. The 3 key rewards and 1 important warning sign could reveal what is quietly shifting beneath the surface.

Grab Holdings (GRAB)

Overview: Grab Holdings runs a superapp across eight Southeast Asian countries that brings together ride hailing, food and parcel delivery, payments, digital banking, lending, insurance and advertising on a single platform for consumers, drivers and merchants.

Operations: Grab generates about US$1.9b from Deliveries, US$1.3b from Mobility, US$379 million from Financial Services and US$4 million from Others.

Market Cap: US$15.38b

Grab Holdings provides exposure to Southeast Asia’s shift toward digital transport, food and finance, and it is already profitable with net margins around 10.7% and earnings growth that has recently moved into a very large acceleration phase. Revenue is forecast to expand faster than the broader US market, analysts see upside to their target prices, and recent news such as the Superbank consolidation and autonomous ride trials with WeRide illustrate new ways the company is trying to deepen its role in the region’s daily life. The trade off is a higher P/E, reliance on external funding and modest current returns on equity, which makes it important to understand what could justify that valuation and where the key pressure points lie.

Grab Holdings’ accelerating shift into profitability, with net margins around 10.7% and fresh moves like Superbank and autonomous trials, has many investors asking what comes next in the region’s superapp race; the analyst forecasts for Grab Holdings could show what expectations are quietly building in the background

Niagen Bioscience (NAGE)

Overview: Niagen Bioscience is a Los Angeles based bioscience company focused on healthy aging, selling TRU NIAGEN supplements and other products built around its proprietary NAD+ boosting ingredient nicotinamide riboside, which it supplies both directly to consumers and as raw material to other manufacturers.

Operations: Niagen Bioscience generates about US$98.6 million from Consumer Products, US$29.1 million from Ingredients, US$2.7 million from Analytical Reference Standards and Services, plus a small segment adjustment.

Market Cap: US$253.8 million

Niagen Bioscience stands out in the penny stock space because it blends a consumer health brand with a growing pharmaceutical angle, backed by its NIAGEN ingredient and a push into IV and injectable products through the Niagen Plus telehealth platform and partnerships with 503B facilities like Olympia Pharmaceuticals and Wells Pharma. Earnings, margins and ROE metrics are already solid for a small cap, while analyst targets and Simply Wall St’s DCF point to valuation that still prices in a lot of caution. On the other hand, an at the market equity program, rising R&D and legal costs, and regulatory and competitive pressure around NAD boosters mean execution really matters, especially as the company juggles buybacks, new launches and supply chain clean up.

Niagen Bioscience’s mix of solid earnings metrics, a consumer brand and a pharma pipeline has many investors wondering what the market might be missing. The analysis report for Niagen Bioscience could surface the one tension that ties valuation, buybacks and that at the market program together.

The 3 stocks in this article are just a starting point, and the full Elite Penny Stocks screener uncovers 19 more companies whose balance sheets and business stories are built around the same kind of high conviction, cash backed narratives. Use Simply Wall St to identify and analyze the specific catalysts, funding profiles and growth stories that matter most to you so you can focus on the highest conviction penny stock ideas.

Take Control of Your Investment Journey

If SIGA Technologies or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Fresh Alternatives Before They Fly

Fresh breakouts, quiet momentum and under the radar stocks do not stay overlooked for long. Scan these curated ideas before the crowd catches up.

• Spot companies building steady compounding power by running the 74 resilient stocks with low risk scores and focus on businesses where resilience and balance sheet strength sit at the center of the story.
• Explore potential infrastructure and hardware momentum with the 51 AI infrastructure stocks and concentrate on companies supplying the picks and shovels behind AI demand.
• Consider real-economy exposure by using the 8 top copper producer stocks to surface producers that may benefit if demand for key industrial metals continues to support long term projects.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.